The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
The purpose of this trial is to assess the effectiveness of TroVax® compared to placebo in
 extending the time to progression in patients with asymptomatic relapsed platinum resistant
 ovarian, fallopian tube or primary peritoneal cancer.The trial will also look at overall
 survival times and quality of life.
A significant number of patients with advanced ovarian cancer develop a "CA-125 relapse"
 without clinical symptoms and with a low volume disease on the CT scan. For this group of
 patients, no survival benefit has been demonstrated from early chemotherapy treatment and, on
 average, the time to start of chemotherapy is 5 months. Such patients could benefit from
 immunotherapy and the time to chemotherapy could potentially be prolonged. Multiple
 immunotherapy agents, such as anti-CA-125 antibodies and various vaccines, have been tested
 and, although there is plenty of evidence of immune response, this has not translated to a
 definitive clinical benefit and is not recommended in clinical practice

 5T4 appears to be highly expressed in ovarian cancer and correlates with more advanced stage
 of disease and poorly differentiated tumours. TroVax®, the vaccine targeting 5T4, has an
 extensive record of safety and efficacy in humans and vaccination in patients with
 colorectal, renal, and prostate cancer resulted in immune cellular and humoral responses and
 signs of clinical benefit.

 We propose a trial of TroVax® vaccination in patients with CA-125-relapsed asymptomatic
 ovarian cancer to assess the clinical efficacy and immunological responses as outlined in
 this protocol. To allow for capture of any delayed response to immunotherapy, patients who
 progress on RECIST 1.1 criteria and who do not experience toxicity from treatment will
 continue on the vaccine/placebo injection until repeat imaging at 8 weeks in order for
 immune-related response criteria (irRC) to be evaluated in addition to RECIST 1.1 criteria
 (these patients as a standard of care would not receive any other therapeutic intervention).
Inclusion Criteria:

 -  Aged ≥18 years with histologically or cytologically proven advanced epithelial ovarian
 carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma

 -  Stage IC1 - III or Stage IVA (pleural effusion only) at diagnosis. (According to new
 FIGO staging effective 01/01/2014)

 -  Completed cytoreductive surgery during the phase of first-line therapy including
 removal of bulky tumour masses and adequate surgical staging including a minimum of
 bilateral salpingo-oophorectomy, hysterectomy and omentectomy

 -  Completed first line platinum-based chemotherapy OR Completed first line
 platinum-based chemotherapy and second line chemotherapy of any type with complete
 response to second line treatment according to RECIST 1.1

 -  Have developed relapse ≥6 months after platinum-based chemotherapy (in the case of
 second relapse, the disease free interval should also be ≥6 months)

 -  Normal CA-125 following platinum-based chemotherapy

 -  Have developed asymptomatic relapse as defined by:

 1. CA125 ≥ 2xULN OR

 2. Low volume radiological disease and CA125>ULN Low volume radiological disease is
 defined as radiologically visible disease excluding intra-hepatic (parenchymal)
 liver or splenic metastases, ascites or pleural effusion thought to require
 drainage within the next 2 months. The following are acceptable: Subcapsular
 liver and splenic lesions, benign lesions or cysts, any suspicious lesions that
 may represent metastases have to be confirmed by further imaging to be
 non-metastatic.

 -  Currently asymptomatic and does not require chemotherapy.

 -  Subject is assumed to be clinically immunocompetent and is free of clinically
 apparent/active autoimmune disease (i.e. no prior confirmed diagnosis or treatment for
 autoimmune disease including Systemic Lupus Erythematosis, Grave's disease,
 Hashimoto's thyroiditis, multiple sclerosis, and rheumatoid arthritis). Note: subjects
 with type I or type II diabetes mellitus can be included, as can subjects with
 controlled and rarely flaring rheumatoid disease (defined as recent flare within 6
 months prior to randomisation/registration)

 -  Subject has adequate bone marrow function as defined by Haemoglobin ≥ 110 g/L, white
 cell count ≥ 3.0 x 10^9/L, Absolute Lymphocyte Count (ALC) ≥ 1.0 x 10^9/L, Absolute
 Neutrophil Count (ANC) ≥1.5 x 10^9/L , Platelet Count ≥ 100 x 10^9/L and <400 x
 10^9/L, Monocytes <0.8 x 10^9/L (for patients who have undergone previous splenectomy
 monocyte counts can be < 1.2 x 10^9/L)

 -  Adequate end-organ function: plasma creatinine ≤ 2x upper limit of normal, AST and/or
 ALT ≤ 2x upper limit of normal, Total Bilirubin ≤ 1.5x upper limit normal

 -  ECOG performance status 0-1

 -  Life expectancy ≥6 months and willing to be available to attend clinic visits for
 treatment and for follow-up

 -  Ability to give written informed consent

 -  To be treated no later than 14 days from randomisation/registration

 Exclusion Criteria:

 -  Carcino-sarcoma/MMMT

 -  Cancer related symptoms, or disease recurrence requiring immediate treatment

 -  Patients with low volume radiological disease in any of the following sites at trial
 entry:

 -  Accumulating ascites thought to require drainage within the next 2 months

 -  Pleural effusion thought to require drainage within the next 2 months

 -  Intraparenchymal Liver and/or splenic metastases

 -  CT scan showing bulky disease requiring chemotherapy, as judged by the investigator

 -  Major surgery/radiation therapy, immunotherapy or chemotherapy completed < 4 weeks
 prior to randomisation/registration

 -  Patients who are deemed as being immunosuppressed, receiving > 4 weeks parenteral or
 oral steroids, (nasal sprays and inhalers are permitted), or receiving
 immunosuppressive therapy following transplant

 -  Chronic (≥ 6 months) oral corticosteroid use except when prescribed as replacement
 therapy in the case of adrenal insufficiency. If previously used for ≥6 months then
 must have discontinued ≥3 months prior to randomisation/registration.

 -  "Currently active" second malignancy, other than non-melanoma skin cancer. Subjects
 are not considered to have a "currently active" malignancy if they have completed
 therapy ≥3 years previously and have no known evidence of residual or recurrent
 disease

 -  Concomitant use of complementary medicines/botanicals. Supplements and conventional
 multivitamins are acceptable.

 -  Evidence of significant clinical disorder or laboratory finding which in the opinion
 of the investigator makes it undesirable for the patient to participate in the trial.
 No participant should have a serious or uncontrolled intercurrent infection (including
 those positive for HIV, hepatitis B or C)

 -  Psychiatric illnesses/social situations that limit compliance with protocol
 requirements

 -  Allergy to egg proteins or history of allergic response to vaccinia vaccines

 -  Prior exposure to TroVax®

 -  Cerebral metastases (known from previous investigations or clinically detectable,
 surgically resected)

 -  Patients on active treatment as part of another clinical trial